Paraoxonase (PON1) 55 polymorphism and association with systemic lupus erythematosus

Iranian Journal of Allergy, Asthma and Immunology

Volumn 12, Issue 3, 2013, Pages 211-219

  Bahrehmand, Fariborz ^a   Vaisi Raygani, Asad ^a,b   Ahmadi, Reza ^a   Kiani, Amir ^c   Rahimi, Zohreh ^a,d   Tavilani, Haidar ^e   Pourmotabbed, Tayebeh ^f  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Arylesterase activity; Blood pressure; Lipid profile; Malondialdehyde; Paraoxonase 55genotype; Systemic lupus erythematosus

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NEOPTERIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84888247347     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21(4): 542-7. (Pubitemid 32323386)
2. Blatter Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguol P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99(1):62-6. (Pubitemid 27058295)
3. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5(9):66-78.
4. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004; 37:1317-23. (Pubitemid 39349235)
5. Pfohl M, Koch M, Enderle MD, Kühn R, Füllhase J, Karsch KR, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes.1999; 48(3):623-7. (Pubitemid 29106879)
6. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Hamda K, et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 2009; 42(9):771-6.
7. Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P . Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006; 54(6):1928-39. (Pubitemid 43877942)
8. Dasgupta S, Demirci FY, Dressen AS, Kao AH, Rhew EY, Ramsey-Goldman R, et al. Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus. Med Genet 2011; 12:7.
9. Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108:83-91. (Pubitemid 47528720)
10. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H, Pourmotabbed T, Shakiba E, et al. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep 2011; 38(8):5421-8.
11. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Taheri M, Bardestani GR, et al. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 2010; 9(3):1735-41.
12. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369(9561):587-96. (Pubitemid 46241445)
13. Farhey Y, Hess EV. Accelerated atherosclerosis and coronary disease in SLE. Lupus 1997; 6(7):572-7. (Pubitemid 27406160)
14. Gaffney PM, Ortmann WA, Selby SA, Shark KB, Ockenden TC, Rohlf KE, et al. Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families. Am J Hum Genet 2000; 66(2):547-56. (Pubitemid 30468833)
15. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42(2):338-46. (Pubitemid 29072852)
16. Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Konieczynska M, Podolec P, et al. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, doublemasked, placebo-controlled study. Arthritis Res Ther 2011; 13(4):R117.
17. Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104(16):1887-93. (Pubitemid 32983229)
18. Bahremand F, Vaisi-Raygani A, Kiani A, Rahimi Z, Tavilani H, Navabi SJ, et al. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus 2012; 21(6):616-24.
19. Kiss E, Seres I, Zsolt K, Tarr T, Csípo I, Szegedi G, et al. [Analysis of paraoxonase activity and lipid profile in lupus patients]. Orv Hetil 2005; 146(47):2395-402.
20. Tewthanom K, Janwityanuchit S, Totemchockchyakarn K, Panomvana D. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci 2008; 11(3):30-4.
21. Ben Mansour R, Lassoued S, Elgaied A, Haddouk S, Marzouk S. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010; 39(3):247-53.
22. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010; 62(7):2064-72.
23. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 2003; 5(5):383-90.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9):1725.
25. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39(3):363-9. (Pubitemid 26085211)
26. Hasselwander O,Savage D,Mc Master D,Loughrey C,Mcnamee P,Middleton D,et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in transplant recipient. Kidney int 1999; 56(1):289-98. (Pubitemid 29300547)
27. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism, Am J Hum Genet 1983; 35(6):1126-38. (Pubitemid 14201166)
28. Asefi M, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, Nomani H, et al. Paraoxonase (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol 2012; 167(6):1279-86.
29. Raygani AV, Rahimi Z, Kharrazi H, Tavilani H, Pourmotaabed A. Association between apolipoprotein E polymorphism blood profiles lipids, lipoproteins and apolipoproteins with Alzheimer's disease. Neurosci Lett 2006; 408(1):68-72. (Pubitemid 44466204)
30. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3(1):73-6. (Pubitemid 23063292)
31. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48(1):26-31.
32. Hayem G, Nicaise-Roland P, Palazzo E, de Bandt M, Tubach F, Weber M, et al. Anti-oxidized low-densitylipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001; 10(5):346-51. (Pubitemid 32520241)
33. Ames PRJ, Alves J, Inanc M, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999; 38(6):529-34. (Pubitemid 29504838)
34. Vaisi-Raygani A, Rahimi Z, Tavilani H, Vaisi-Raygani H, Kiani A, Aminian M, et al. Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease. Mol Biol Rep 2012; 39(3):2723-31.
35. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Nomani H, Saidi M, Bahrehmand F, et al. The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease. Clin Biochem 2010; 43(15):1189-94.
36. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 2007; 40(15):1150-6. (Pubitemid 47379326)
37. Kharrazi H, Vaisi Raygani A, Sabokroh AR, Pourmotabbed T. Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem 2006; 39(6):613-6.
38. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 2001; 276(3):1923-9. (Pubitemid 32109669)
39. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25):2407-15. (Pubitemid 37542989)
40. Rho YH, Solus J, Raggi P, Oeser A, Gebretsadik T, Shintani A, et al. Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011; 63(4):535-41.